Improved risk–benefit ratio for topical triamcinolone acetonide in Transfersome® in comparison with equipotent cream and ointment: a randomized controlled trial

H. Fesq,J. Lehmann,A. Kontny,I. Erdmann,K. Theiling,M. Rother,J. Ring,G. Cevc,D. Abeck
DOI: https://doi.org/10.1046/j.1365-2133.2003.05475.x
IF: 11.113
2003-09-01
British Journal of Dermatology
Abstract:Background  Transfersome® is a drug delivery technology based on highly deformable, ultraflexible lipid vesicles which penetrate the skin when applied non‐occlusively.
What problem does this paper attempt to address?